Marian P Jarlenski1, Nicole C Paul, Elizabeth E Krans. 1. Department of Health Policy and Management, University of Pittsburgh, the University of Pittsburgh, and the Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
OBJECTIVE: To assess trends in polysubstance use among pregnant women with opioid use disorder in the United States. METHODS: We conducted a time trend analysis of pooled, cross-sectional data from the National Inpatient Sample, an annual nationally representative sample of U.S. hospital discharge data. Among 38.0 million females aged 15-44 years with a hospitalization for delivery from 2007 to 2016, we identified 172,335 pregnant women with an International Classification of Diseases, Ninth Revision, Clinical Modification or International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis of opioid use disorder. Polysubstance use among pregnant women with opioid use disorder was defined as at least one co-occurring diagnosis of other substance use, including alcohol, amphetamine, cannabis, cocaine, sedative, or tobacco. We fit weighted multivariable logistic regression models to produce nationally representative estimates, including an interaction between year and rural compared with urban county of residence; controlled for age, race, and insurance type. Average predicted probabilities and 95% CIs were derived from regression results. RESULTS: Polysubstance use among women with opioid use disorder increased from 60.5% (95% CI 58.3-62.8%) to 64.1% (95% CI 62.8%-65.3%). Differential time trends in polysubstance use among women with opioid use disorder were found in rural compared with urban counties. Large increases in amphetamine use occurred among those in both rural and urban counties (255.4%; 95% CI 90.5-562.9% and 150.7%; 95% CI 78.2-52.7%, respectively), similarly to tobacco use (30.4%; 95% CI 16.9-45.4% and 23.2%; 95% CI 15.3-31.6%, respectively). Cocaine use diagnoses declined among women with opioid use disorder at delivery in rural (-70.5%; 95% CI -80.4% to -55.5%) and urban (-61.9%; 95% CI -67.6% to -55.1%) counties. Alcohol use diagnoses among those with opioid use disorder declined -57% (95% CI -70.8% to -37.7%) in urban counties but did not change among those in rural counties. CONCLUSION: Over the past decade, polysubstance use among pregnant women with opioid use disorder has increased more rapidly in rural compared with urban counties in the United States, with amphetamines and tobacco use increasing most rapidly.
OBJECTIVE: To assess trends in polysubstance use among pregnant women with opioid use disorder in the United States. METHODS: We conducted a time trend analysis of pooled, cross-sectional data from the National Inpatient Sample, an annual nationally representative sample of U.S. hospital discharge data. Among 38.0 million females aged 15-44 years with a hospitalization for delivery from 2007 to 2016, we identified 172,335 pregnant women with an International Classification of Diseases, Ninth Revision, Clinical Modification or International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis of opioid use disorder. Polysubstance use among pregnant women with opioid use disorder was defined as at least one co-occurring diagnosis of other substance use, including alcohol, amphetamine, cannabis, cocaine, sedative, or tobacco. We fit weighted multivariable logistic regression models to produce nationally representative estimates, including an interaction between year and rural compared with urban county of residence; controlled for age, race, and insurance type. Average predicted probabilities and 95% CIs were derived from regression results. RESULTS: Polysubstance use among women with opioid use disorder increased from 60.5% (95% CI 58.3-62.8%) to 64.1% (95% CI 62.8%-65.3%). Differential time trends in polysubstance use among women with opioid use disorder were found in rural compared with urban counties. Large increases in amphetamine use occurred among those in both rural and urban counties (255.4%; 95% CI 90.5-562.9% and 150.7%; 95% CI 78.2-52.7%, respectively), similarly to tobacco use (30.4%; 95% CI 16.9-45.4% and 23.2%; 95% CI 15.3-31.6%, respectively). Cocaine use diagnoses declined among women with opioid use disorder at delivery in rural (-70.5%; 95% CI -80.4% to -55.5%) and urban (-61.9%; 95% CI -67.6% to -55.1%) counties. Alcohol use diagnoses among those with opioid use disorder declined -57% (95% CI -70.8% to -37.7%) in urban counties but did not change among those in rural counties. CONCLUSION: Over the past decade, polysubstance use among pregnant women with opioid use disorder has increased more rapidly in rural compared with urban counties in the United States, with amphetamines and tobacco use increasing most rapidly.
Authors: Lindsay K Admon; Gavin Bart; Katy B Kozhimannil; Caroline R Richardson; Vanessa K Dalton; Tyler N A Winkelman Journal: Am J Public Health Date: 2018-11-29 Impact factor: 9.308
Authors: Hendrée E Jones; Sarah H Heil; Michelle Tuten; Margaret S Chisolm; Julianne M Foster; Kevin E O'Grady; Karol Kaltenbach Journal: Drug Alcohol Depend Date: 2012-12-29 Impact factor: 4.492
Authors: D M Coviello; A I Alterman; M J Rutherford; J S Cacciola; J R McKay; D A Zanis Journal: Drug Alcohol Depend Date: 2001-01-01 Impact factor: 4.492
Authors: Elizabeth E Krans; Melinda Campopiano; Lisa M Cleveland; Daisy Goodman; Deborah Kilday; Susan Kendig; Lisa R Leffert; Elliott K Main; Kathleen T Mitchell; David T O'Gurek; Robyn D'Oria; Deidre McDaniel; Mishka Terplan Journal: Obstet Gynecol Date: 2019-08 Impact factor: 7.661
Authors: Van T Tong; Patricia M Dietz; Brian Morrow; Denise V D'Angelo; Sherry L Farr; Karilynn M Rockhill; Lucinda J England Journal: MMWR Surveill Summ Date: 2013-11-08
Authors: Marian Jarlenski; Elizabeth E Krans; Qingwen Chen; Scott D Rothenberger; Abigail Cartus; Kara Zivin; Lisa M Bodnar Journal: Drug Alcohol Depend Date: 2020-08-20 Impact factor: 4.492
Authors: Kara Zivin; Lindsay Allen; Andrew J Barnes; Stefanie Junker; Joo Yeon Kim; Lu Tang; Susan Kennedy; Katherine A Ahrens; Marguerite Burns; Sarah Clark; Evan Cole; Dushka Crane; David Idala; Paul Lanier; Shamis Mohamoud; Marian Jarlenski; Mary Joan McDuffie; Jeffery Talbert; Adam J Gordon; Julie M Donohue Journal: Med Care Date: 2022-07-15 Impact factor: 3.178
Authors: Yitong Alice Gao; Coleman Drake; Elizabeth E Krans; Qingwen Chen; Marian P Jarlenski Journal: J Addict Med Date: 2022-03-03 Impact factor: 4.647